Immunotherapy plus chemo shows promise in rectal cancer trial

NCT ID NCT07291401

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) to standard chemoradiotherapy before surgery can improve outcomes for people with locally advanced rectal cancer. About 108 participants will be randomly assigned to receive either the standard treatment or the standard treatment plus immunotherapy. The goal is to see if the combination leads to a higher rate of complete tumor disappearance and allows more patients to avoid surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Iparomlimab and tuvonralimab (QL1706) combined with chemotherapy (CAPOX) and radiotherapy
What this could lead to
If successful, this could offer a more effective neoadjuvant treatment for locally advanced rectal cancer, potentially increasing the chance of complete tumor response and organ preservation.
What could go wrong
This is an early phase 2 trial with only 108 participants, so results may not apply to all patients. Adding immunotherapy to standard treatment may increase side effects, and it's unknown if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.